Sorafenib-induced erythema multiforme-Reference-Cited by-同舟云学术

Sorafenib-induced erythema multiforme

Published:2007-03 Issue:3 Volume:56 Page:527-528
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

MacGregor Jennifer L.,Silvers David N.,Grossman Marc E.,Sherman William H.

Publisher

Elsevier BV

Subject

Dermatology

Reference5 articles.

1. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma;Ratain;J Clin Oncol,2006

2. Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumors: is rash associated with treatment outcome?;Strumberg;Eur J Cancer,2006

3. BAY 43-9006 exhibits broad spectrum oral anti-tumor activity and targets the Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis;Wilhelm;Cancer Res,2004

4. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors;Strumberg;J Clin Oncol,2005

5. Nexavar (sorafenib) tablets 200 mg [product information]. Bayer Pharmaceuticals, West Haven, CT. Available at: http://www.univgraph.com/bayer/inserts/NexavarNAV_PI.pdf. Accessed June 29, 2006.

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sorafenib-Induced Erythema Multiforme Major and Severe Hepatic Failure in Metastatic Hepatocellular Carcinoma: A Case Report;Cureus;2024-03-29

2. Reactive Inflammatory Erythemas;Rook's Textbook of Dermatology;2024-03-19

3. Dermatological adverse drug reactions to tyrosine kinase inhibitors: a narrative review;Clinical and Experimental Dermatology;2023-02-20

4. Evaluation of Delayed-Type Hypersensitivity to Antineoplastic Drugs—An Overview;Cancers;2023-02-14

5. Anti-angiogenic effect of the combination of low-dose sorafenib and EGCG in HCC-induced Wistar rats;F1000Research;2022-12-21